|Application ||WB, E|
|Calculated MW||28671 Da|
|Antigen Region||166-197 aa|
|Other Names||Kallikrein-2, Glandular kallikrein-1, hGK-1, Tissue kallikrein-2, KLK2|
|Target/Specificity||This Kallikrein 2 (KLK2) antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 166-197 amino acids from the C-terminal region of human Kallikrein 2 (KLK2).|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||Kallikrein 2 (KLK2) Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Glandular kallikreins cleave Met-Lys and Arg-Ser bonds in kininogen to release Lys-bradykinin.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Kallikreins are a group of serine proteases manifesting diverse physiological functions. The glandular kallikreins are a distinct group of serine proteases with an ability to release vasoactive peptides from kininogen in vitro, although the kininogenase activity of different kallikreins is highly variable. Glandular kallikreins cleave Met-Lys and Arg-Ser bonds in kininogen to release Lys-bradykinin. Many kallikrein genes are differentially expressed in various malignancies. Human glandular kallikrein (hK2; encoded by the KLK2 gene) is an emerging tumor marker for prostate cancer.
Haese, A., et al., J Urol. 2005 Mar;173(3):752-6. Chiang, C.H., et al., J Urol. 2005 Feb;173(2):429-32. Clements, J.A., et al., Crit Rev Clin Lab Sci. 2004;41(3):265-312. Borgono, C.A., et al., Mol Cancer Res. 2004 May;2(5):257-80. Yousef, G.M., Clin Biochem. 2003 Sep;36(6):443-52.
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.